INVAMED integrates AI with cardiac technologies for a heart-healthy future
Turkish medical firm INVAMED has revolutionized cardiac care by combining respiratory-controlled cardiac pacemaker and Implantable Cardioverter Defibrillator (ICD) technologies with artificial intelligence, ushering in a new era of heart health.
Developed in collaboration with experts in cardiology and cardiac surgery, found in many countries by INVAMED Medical Innovation Institute, the respiratory-controlled cardiac pacemaker and ICD technologies, which are the result of years of meticulous research,are presented to the world of medicine by integrating with artificial intelligence.
According to INVAMED, the respiratory-controlled cardiac pacemaker is supported by artificial intelligence algorithms that can respond sensitively to patient physiology.
This way, the heart’s electrical activity is optimized based on real-time changes in respiratory rate and depth.
This innovative approach enhances energy efficiency and cardiac performance.
The ICD technology, while capable of detecting ventricular arrhythmias that pose potential life threats and intervening instantly, is also equipped with an upgradeable intelligence feature that makes it easier for doctors to create specific treatment protocols.
Thanks to the simulator developed by INVAMED, the performance of these technologies in a clinical setting can be tested in advance, thus maximizing the safety and effectiveness of treatment processes.
According to the World Health Organization (WHO) statistics, cardiovascular diseases cause the death of 17 million people every year. INVAMED aims to change this ‘grim’ picture of heart health with its innovative technologies developed through R&D efforts.
INVAMED President Rasit Dinc, whose views are included in the statement, stated that these developments symbolize the beginning of a new era in cardiovascular treatment.
“As INVAMED, we will continue to stay at the forefront of medical innovation in the light of our scientific research,” Dinc said.
Source: aa